Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
Repository logoRepository logo
  • Communities & Collections
  • All Contents
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Evlice A."

Now showing 1 - 2 of 2
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Identification of the variations in the CPT1B and CHKB genes along with the HLA-DQB1*06:02 allele in Turkish narcolepsy patients and healthy persons
    (Mary Ann Liebert Inc., 2014) Cingoz S.; Agilkaya S.; Oztura I.; Eroglu S.; Karadeniz D.; Evlice A.; Altungoz O.; Yilmaz H.; Baklan B.
    Background: The HLA-DQB1*06:02 allele across all ethnic groups and the rs5770917 variation between CPT1B and CHKB genes in Japanese and Koreans are common genetic susceptibility factors for narcolepsy. This comprehensive genetic study sought to assess variations in CHKB and CPT1B susceptibility genes and HLA-DQB1*06:02 allele status in Turkish patients with narcolepsy and healthy persons. Methods: CHKB/CPT1B genes were sequenced in patients with narcolepsy (n=37) and healthy persons (n=100) to detect variations. The HLA-DQB1*06:02 allele status was determined by sequence specific polymerase chain reaction. Results: The HLA-DQB1*06:02 allele was significantly more frequent in narcoleptic patients than in healthy persons (p=2×10-7) and in patients with narcolepsy and cataplexy than in those without (p=0.018). The mean of the multiple sleep latency test, sleep-onset rapid eye movement periods, and frequency of sleep paralysis significantly differed in the HLA-DQB1*06:02-positive patients. rs5770917, rs5770911, rs2269381, and rs2269382 were detected together as a haplotype in three patients and 11 healthy persons. In addition to this haplotype, the indel variation (rs144647670) was detected in the 5′ upstream region of the human CHKB gene in the patients and healthy persons carrying four variants together. Conclusion: This study identified a novel haplotype consisting of the indel variation, which had not been detected in previous studies in Japanese and Korean populations, and observed four single-nucleotide polymorphisms in CHKB/CPT1B. The study confirmed the association of the HLA-DQB1*06:02 allele with narcolepsy and cataplexy susceptibility. The findings suggest that the presence of HLA-DQB1*06:02 may be a predictor of cataplexy in narcoleptic patients and could therefore be used as an additional diagnostic marker alongside hypocretin. © 2014 Mary Ann Liebert, Inc.
  • No Thumbnail Available
    Item
    Other primary headache disorders: Data from the HEAD-MENA-A study in Africa, Asia, and the Middle East
    (Elsevier B.V., 2024) Atalar A.Ç.; Genç H.; Ur Özçelik E.; Bolay H.; Uluduz D.; Unal-Cevik, I; Kissani N.; Luvsannorov O.; Togha M.; Ozge A.; Baykan B.; Cakan M.; Ak A.K.; Celik F.; Orun M.O.; Seker D.; Kucuk A.; Ozkan S.; Kiraz M.; Sirin T.C.; Ocal R.; Hakyemez H.A.; Yener M.O.; Serim V.A.; Cınar N.; Unal E.D.; Domac F.M.; Ates M.F.; Turkoglu B.G.; Gursoy G.; Cekic S.; Aslan S.K.; Agırcan D.; Oktar A.C.; Demirel E.A.; Gelener P.; Ibrahim E.A.A.E.; Evlice A.; Gorken G.; Sanlı Z.S.; Bayır B.R.H.; Tepe N.; Okluoglu T.; Demir T.G.; Badr M.Y.; Vurallı D.; Jafari E.; Polat B.; Ermis A.; Khanmammadov E.; Yolcu O.; Kul B.; Sakadi F.; Ulutas S.; Akturk T.; Ketema T.M.; Lala S.; Cedric A.P.S.A.; Velioglu S.K.; Kırbasoglu O.; Moustafa R.R.; Nowar A.G.; Kabay S.C.; Gumanovna V.K.; Yifru Y.M.; Nasergivehchi S.; Azizova I.; Kizek O.; Ekizoglu E.; Orhan E.K.; Melka D.; Alemayehu B.
    Objective: Other primary headache disorders (OPHD) are under-investigated compared to frequent primary headache types like migraine, tension-type headache, and trigeminal autonomic cephalalgias. Knowledge of the distribution and characteristics of OPHD subtypes is crucial for their recognition. We aimed to determine the prevalence at the hospital and headache clinics and clinical characteristics of OPHDs in patients from 13 countries. Methods: We analyzed a large dataset from the cross-sectional study Head-MENA-A (Middle East, North Africa, Asia). Consecutive patients over 10 years of age presenting with headaches were included from outpatient, inpatient, and emergency settings. A structured questionnaire addressing demographics, headache characteristics, accompanying symptoms, and triggers was administered. Headache subtypes were diagnosed according to the ICHD-3 criteria. Results: Among patients complaining of headaches (n = 3722), 106 (2.9%) were diagnosed with OPHD. Fifty-two patients (1.4% of all headache patients) had only OPHD, while 54 (1.5%) had both OPHD and a co-existing primary headache (mostly migraine). All OPHDs were more common in females. The most frequent subtypes were new daily persistent headache and primary stabbing headache (0.2% each among all admitted patients). Photophobia and phonophobia were the most frequent accompanying symptoms, while physical activity (28.8%), stress (15.4%), and the Valsalva maneuver (15.4%) were the most common triggering factors. The majority of triggering factors were more pronounced in patients with both migraine and OPHD. Conclusions: Other primary headaches are rare and heterogeneous. Their high co-existence with migraine suggests shared predisposing factors, hinting at a “headache continuum” concept for primary headaches. © 2024 Elsevier B.V.

Manisa Celal Bayar University copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback